News

Current News    |    Archive    

2015

November 2015

UVA BME and Coulter Program Collaborate with Bio-Med Tech Girls

Coulter Investment Forum Coming in 2016

RIVANNA Commences Sales of Accuro™, Continues Discussions with Three Potential Corporate Partners

September 2015

Cell Surface Discovery May Lead to Major Breakthrough in Cancer Treatment

August 2015

Texas Cardiac Arrhythmia Institute at St. David's Medical Center First in US to Use EpiAccess™ System

HemoSonics Awarded $1M Phase II Grant from the US Air Force

June 2015

TypeZero Tech: More High Hopes for Closed Loop Commercialization

Accuro Handheld Ultrasound Needle Guidance System Cleared by FDA

HemoShear Expands Focus to Discovery of Therapeutics

January 2015

HemoShear Announces Collaboration with Pfizer Inc. To Help Identify and Predict Drug-Induced Vascular Injury for Early Stage Compounds


2014

November 2014

EpiEP Inc. Receives FDA 510(k) Clearance for EpiAccess System

August 2014

BioCentury Newsletter: Emerging Company Profile on NeoAntigenics

June 2014

Innovative Alumni Aiming to Put Ultrasound in Docs' Pockets

May 2014

HemoShear Secures $8.7 Million in Private Equity Offering

April 2014

PsiKick's batteryless sensors poised for coming 'Internet of things'

March 2014

U.Va.-UofM-UW Start-Up Announces NEA Venture Funding to Accelerate Energy-Efficient Wireless Technology

January 2014

U.Va. Spinoff Neoantigenics Announces Collaboration with Pfizer, Investment from CIT to Develop Antibody-based Therapeutics For Cancer

UVA, Russian Experts Target Drug-Resistant TB


2013

September 2013

HemoShear Advances Human Relevant Science to Predict New Drug Safety


2012

November 2012

Rivanna Medical featured in Daily Progress

October 2012

HemoShear closes $4M funding round

September 2012

HemoShear closes $1 million dollar debt financing

July 2012

HemoSonics received $100,000 in funding from CIT

July 2012

HemoShear featured in Daily Progress news


2011

December 2011

The Center for Innovative Technology (CIT) recently announced its grant awards for Fall 2011. Several Coulter funded start-up companies were awarded funds through the Commonwealth Commercialization Research Fund.

  • HemoSonics, LLC - $100,000 in SBIR matching funds
    HemoSonics is a company focused on the use of ultrasound to diagnose blood-clotting disorders. (hemosonics.com)

  • iTi Health, Inc., - $100,000 in SBIR matching funds
    iTi has developed a platform technology, Phagemark, that identifies and develops biomarkers and binding peptides to create targeted therapeutics and diagnostic imaging tools.

  • HemoShear, LLC - $500,000 through the commercialization program
    HemoShear has developed a recalibration process to return the function of cultured cells to their in-vivo characteristics by applying region specific hemodynamic forces. This grant was awarded for work on a project entitled “Interspecies Drug-Induced Vascular Injury (DIVI) Consortium”. (www.hemoshear.com/)

  • RetiVue, LLC - $250,000 through the commercialization program
    RetiVue was awarded the funding for its project entitled "Bringing Affordable Retinal Screening Technology and Services to the Primary Care Clinic" that is working to commercialize a retinal camera to diagnose and prevent the onset of blindness. (www.retivue.com/)

The grants awarded were part of the $3.6 million that CIT distributed to start-up companies in Virginia this year. More information on the awards is available at www.prweb.com/releases/2011/12/prweb9053447.htm.

October 2011

FDA To Companion DX Developers: Pre-Trial Assay Validation is Key (pdf)

May 3, 2011

The Wallace H. Coulter Foundation Translational Research Partnership Award Creates a $20 Million U.Va. Endowment for Translational Research in Biomedical Innovation. Read more...


2010

December 3, 2010

Twelve UVa-related biotechnology firms were awarded over $2.7 million in grants under the new Qualified Therapeutic Discovery Project Program. To read more, please visit UVa Today.


2008

Fund Established to Support Biomedical Innovation and Research at U.Va.
March 20, 2008: The University of Virginia's Department of Biomedical Engineering has been selected by Johnson & Johnson as the recipient of a grant to finance biomedical translational research, which will promote the advancement of treatments to improve patient care.

Fund Established to Support Biomedical Innovation and Research at U.Va. (pdf)


Coulter ROPe Funds

Coulter Partnership announces new and innovate source of funds to support faculty translational research. Coulter ROPE Funds (pdf)